Clinical Trial: Triapine and Lutetium Lu 177 Dotatate for Neuroendocrine Tumors


What is PRRT?

I’m guessing most of my readers know what Peptide Receptor Radiotherapy (PRRT) is.  But for those new to this field, read more here

What is Triapine?

Triapine is a ribonucleotide reductase (RNR) inhibitor, I.e. it helps repair DNA.  When I research this drug, I can see it is used in numerous examples of clinical trials in an anti-cancer setting alongside radiotherapy and chemotherapy, in many cancers.

Triapine in NET

There is currently a trial of Triapine with Lutathera (PRRT) (11 major US hospitals).  This study was testing the hypothesis that triapine is an effective radiation sensitizer that can be safely combined with peptide receptor radionuclide therapy and can improve antitumor activity of Lutetium Lu 177 Dotatate, e.g. increase the objective response rate (ORR) above that found in standalone clinical trials, e.g. NETTER-1.   A trial sponsored by Markey Cancer Center has recently completed Phase 1 and has been granted permission to progress to a randomised phase 2 study, a clear indication the Phase 1 study was successful and warranted further progression.  

The Clinical Trial Document (phase 1) – NCT04234568

Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors – Full Text View –

It is not yet known whether the existing Phase 1 clinical trials doc above will be converted to Phase 2 or a new one will be entered into the database.  Nor is it yet known that the trial locations will be less, the same, or extended; I will keep you informed via this post.

Phase 1 trial data

To be confirmed. Watch this space.

Additional Information

This trial is also evaluating NETest, a novel blood-based test that evaluates levels of 51 neuroendocrine tumor gene transcripts. In addition, the study will correlate clinical outcome with baseline somatostatin receptor density, somatic tumor mutations and germline mutations.

Read more about NETest by clicking here

General Clinical Trials Disclaimer

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact. 

Inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan. 



I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.  Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional as they are not members of the private group or followers of my sites in any official capacity.  Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.

Subscribe to my newsletter

Thanks for reading.


I’m also active on Facebook. Like my page for even more news. Help me build up my new site here – click here and ‘Like’

Sign up for my newsletters – Click Here


My Diagnosis and Treatment History

Follow me on twitter

Check out my online presentations

Check out my WEGO Health Awards

Remember ….. in the war on Neuroendocrine Cancer, let’s not forget to win the battle for better quality of life!

patients included

Please Share this post for Neuroendocrine Cancer awareness and to help another patient


A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (MAST)

A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors (MAST) Neuroendocrine

Read More »

Neuroendocrine Cancer: When you get years added to your life, it’s important to get life added to your years

Self Pity or Self Help?  I’m not one for wallowing in self-pity or accepting invites to pity parties.  It’s not my style. Things happen in

Read More »

Opinion: Neuroendocrine Cancer – remission, cancer-free, no evidence of disease

An opinion post Cure I once wrote an article called “Neuroendocrine Cancer – can it be cured“.  In that article, I covered the fact that

Read More »

Clinical Trial: Phase 1b/3 Targeted Alpha-Emitter PRRT RYZ101 (Ac225)

What is RYZ101? RYZ101 is an investigational targeted alpha-emitter radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing SSTR2. RYZ101

Read More »

Lung nodules – something or nothing?

Background A focus on the issue of Lung nodules given I see these mentioned all the time in my online patient group, on many occasions

Read More »

Awareness Post – Neuroendocrine Cancer in children and adolescents

September is Childhood Cancer Awareness Month!  The newspapers and social media will no doubt be featuring many children’s cancer articles. I personally cannot begin to

Read More »

I love comments - feel free!

%d bloggers like this: